查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
Brugada症候群的按全球市場 - 市場佔有率，規模，趨勢，產業分析:診斷，各治療，各最終用途，各地區，市場區隔預測(2023年～2032年)
市場調查報告書
商品編碼
1238769

Brugada症候群的按全球市場 - 市場佔有率，規模，趨勢，產業分析:診斷，各治療，各最終用途，各地區，市場區隔預測(2023年～2032年)

Brugada Syndrome Market Share, Size, Trends, Industry Analysis Report, By Diagnosis (Electrocardiogram, Electrophysiology test, Genetic testing); By Treatment; By End-Use; By Region; Segment Forecast, 2023 - 2032
出版日期: | 出版商: Polaris Market Research | 英文 116 Pages | 商品交期: 最快1-2個工作天內

價格

全球Brugada症候群的市場規模，預計至2032年達到23億8,000萬美元。

本報告提供全球Brugada症候群市場調查，市場概要，市場規模和預測，趨勢，促進因素、阻礙因素，各診斷、各治療、各最終用途、各地區等的分析，再加上企業簡介等資訊。

目錄

第1章 簡介

  • 報告的說明
    • 調查的目的
    • 市場範圍
    • 前提條件
  • 利害關係者

第2章 摘要整理

  • 市場概況

第3章 調查手法

  • 概要
    • 資料探勘
  • 資訊來源
    • 一次資訊
    • 二次資訊

第4章 全球Brugada症候群市場洞察

  • Brugada症候群市場 - 產業的概述
  • Brugada症候群市場動態
    • 促進因素和機會
    • 阻礙因素與課題
  • 波特的五力分析
    • 供給企業談判力
    • 新加入廠商的威脅
    • 買方議價能力
    • 替代品的威脅
    • 現有企業間的競爭力
  • PESTEL分析
  • Brugada症候群的產業趨勢
  • 價值鏈分析
  • COVID-19影響分析

第5章 全球Brugada症候群市場:各診斷

  • 主要調查結果
  • 簡介
    • 全球Brugada症候群市場，各診斷(2019年～2032年)
  • 心電圖
    • 全球Brugada症候群市場，心電圖，各地區(2019年～2032年)
  • 電生理學檢驗
    • 全球Brugada症候群市場，電生理學檢查，各地區(2019年～2032年)
  • 遺傳基因檢驗
    • 全球Brugada症候群市場，遺傳基因檢查，各地區(2019年～2032年)
  • 其他
    • 全球Brugada症候群市場，其他，各地區(2019年～2032年)

第6章 全球Brugada症候群市場:各治療

  • 主要調查結果
  • 簡介
    • 全球Brugada症候群市場，各治療(2019年～2032年)
  • 置入式除顫器
    • 全球Brugada症候群市場，置入式除顫器，各地區(2019年～2032年)
  • 藥物療法
    • 全球Brugada症候群市場，藥物療法，各地區(2019年～2032年)
    • 抗心律不整藥
    • 向精神藥
    • 麻醉劑、止痛藥
  • 其他
    • 全球Brugada症候群市場，其他，各地區(2019年～2032年)

第7章 全球Brugada症候群市場:各最終用途

  • 主要調查結果
  • 簡介
    • 全球Brugada症候群市場，各最終用途(2019年～2032年)
  • 醫院、診療所
    • 全球Brugada症候群市場，醫院、診療所，各地區(2019年～2032年)
  • 外科中心
    • 全球Brugada症候群市場，外科中心，各地區(2019年～2032年)
  • 診斷中心
    • 全球Brugada症候群市場，診斷中心，各地區(2019年～2032年)
  • 其他
    • 全球Brugada症候群市場，其他，各地區(2019年～2032年)

第8章 全球Brugada症候群市場:各地區

  • 主要調查結果
  • 簡介
    • Brugada症候群市場評估，各地區(2019年～2032年)
  • Brugada症候群市場 - 北美
    • 北美:Brugada症候群市場，各診斷(2019年～2032年)
    • 北美:Brugada症候群市場，各最終用途(2019年～2032年)
    • 北美:Brugada症候群市場，各治療(2019年～2032年)
    • Brugada症候群市場 - 美國
    • Brugada症候群市場 - 加拿大
  • Brugada症候群市場 - 歐洲
    • 歐洲:Brugada症候群市場，各診斷(2019年～2032年)
    • 歐洲:Brugada症候群市場，各最終用途(2019年～2032年)
    • 歐洲:Brugada症候群市場，各治療(2019年～2032年)
    • Brugada症候群市場 - 英國
    • Brugada症候群市場 - 法國
    • Brugada症候群市場 - 德國
    • Brugada症候群市場 - 義大利
    • Brugada症候群市場 - 西班牙
    • Brugada症候群市場 - 荷蘭
    • Brugada症候群市場 - 俄羅斯
  • Brugada症候群市場 - 亞太地區
    • 亞太地區:Brugada症候群市場，各診斷(2019年～2032年)
    • 亞太地區:Brugada症候群市場，各最終用途(2019年～2032年)
    • 亞太地區:Brugada症候群市場，各治療(2019年～2032年)
    • Brugada症候群市場 - 中國
    • Brugada症候群市場 - 印度
    • Brugada症候群市場 - 馬來西亞
    • Brugada症候群市場 - 日本
    • Brugada症候群市場 - 印尼
    • Brugada症候群市場 - 韓國
  • Brugada症候群市場 - 中東、非洲
    • 中東、非洲:Brugada症候群市場，各診斷(2019年～2032年)
    • 中東、非洲:Brugada症候群市場，各最終用途(2019年～2032年)
    • 中東、非洲:Brugada症候群市場，各治療(2019年～2032年)
    • Brugada症候群市場 - 沙烏地阿拉伯
    • Brugada症候群市場 - 阿拉伯聯合大公國
    • Brugada症候群市場 - 以色列
    • Brugada症候群市場 - 南非
  • Brugada症候群市場 - 南美
    • 南美:Brugada症候群市場，各診斷(2019年～2032年)
    • 南美:Brugada症候群市場，各最終用途(2019年～2032年)
    • 南美:Brugada症候群市場，各治療(2019年～2032年)
    • Brugada症候群市場 - 墨西哥
    • Brugada症候群市場 - 巴西
    • Brugada症候群市場 - 阿根廷

第9章 競爭情形

  • 擴大和收購的分析
    • 擴大
    • 收購
  • 夥伴關係/合作/協定/公開

第10章 企業簡介

  • Abbott
  • Boehringer Ingelheim International
  • Catalyst Pharmaceuticals Inc
  • Ionis Pharmaceuticals
  • Leadiant Biosciences Inc
  • Natera Inc
  • Novo Nordisk A/S
  • Pfizer Inc
  • PTC Therapeutics
  • Roche
  • Salarius Pharmaceuticals Inc
  • Takeda Pharmaceuticals
  • Novartis AG
Product Code: PM3032

The global brugada syndrome market size is expected to reach USD 2.38 billion by 2032, according to a new study by Polaris Market Research. The report "Brugada Syndrome Market Share, Size, Trends, Industry Analysis Report, By Diagnosis (Electrocardiogram, Electrophysiology, Genetic testing, Others); By Treatment; By End-User; By Region; Segment Forecast, 2023 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Factors driving the worldwide Brugada syndrome treatment market include an increase in the incidence of the disease, an increase in healthcare spending, an increase in therapeutic demand, advancements in diagnostic technology, and increased government activities to raise awareness. Other reasons that contribute to market expansion include the influence of addiction to smoking, changes in lifestyle, and western culture among adults. Furthermore, exposure to hazardous chemicals and environmental pollution drives market expansion.

According to World Health Organization (WHO) estimates, as of 2019, 17.9 million people died as a result of cardiovascular diseases, accounting for more than 32% of all global fatalities. Furthermore, heart attacks and stroke account for approximately 85% of CVD-related fatalities.

According to The National Organization for Rare Disorders, the frequency of Brugada Syndrome in the United States was projected to be 5 in 10,000 persons in 2019. Furthermore, increased awareness of genetic disorders, as well as a burgeoning pharmaceutical and biotechnology sector, will provide attractive growth opportunities for the market throughout the forecast period.

The demand for heart transplantation has increased considerably in recent years due to a rise in the prevalence of heart failure. However, the failure to meet current demand has resulted in a global scarcity of eligible organs for transplantation. According to the National Database of the Health Coffers and Services Administration of the United States, there were around 4150 campaigners on the heart transplant staying list, as of March 2020.

Brugada syndrome has progressed from an uncommon disorder to the second biggest cause of death among young adults in some countries, after only vehicle accidents. The syndrome, which is electrocardiographically characterized by distinct Pulmonary hypertension in the right precordial leads, is associated with a considerable risk of sudden cardiac death in young and otherwise healthy adults, but less typically in newborns and children.

Brugada Syndrome Market Report Highlights:

  • The hospital & clinics sector segment has contributed immensely due to the availability and accessibility of novel therapies and equipment.
  • Implantable cardioverter defibrillator treatment is expected to witness significant growth over the forecast period owing to wide use of this treatment in BrS. It is known to be a significant cause of sudden cardiac mortality in young people.
  • North America dominates the revenue share and is primarily driven by the rising use of electrocardiograms, electrophysiology (EP) tests for illness diagnosis, and a large population base diagnosed with heart-related ailments.
  • The global players include: Abbott, Boehringer Ingelheim, Catalyst Pharmaceuticals, Ionis Pharmaceuticals, Leadiant Biosciences, Natera, Novo Nordisk, Pfizer, PTC Therapeutics, Roche, Salarius Pharmaceuticals, Takeda Pharmaceuticals, Novartis.

Polaris Market Research has segmented the Brugada market report based on diagnosis, treatment, end-use, and region:

Brugada Syndrome, Diagnosis Outlook (Revenue - USD Billion, 2019 - 2032)

  • Electrocardiogram
  • Electrophysiology test
  • Genetic testing
  • Others

Brugada Syndrome, Treatment Outlook (Revenue - USD Billion, 2019 - 2032)

  • Implantable cardioverter defibrillator
  • Drug Therapy
  • Antiarrhythmic Drugs
  • Psychotropic Drugs
  • Anesthetics/Analgesics
  • Others

Brugada Syndrome, End-Use Outlook (Revenue - USD Billion, 2019 - 2032)

  • Hospitals and clinics
  • Surgical centers
  • Diagnostic centers
  • Others

Brugada Syndrome, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Russia
    • Netherlands
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Indonesia
    • Malaysia
  • Latin America
    • Argentina
    • Brazil
    • Mexico
  • Middle East & Africa
    • UAE
    • Saudi Arabia
    • Israel
    • South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Brugada Syndrome Market Insights

  • 4.1. Brugada Syndrome Market - Industry Snapshot
  • 4.2. Brugada Syndrome Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Rising frequency of cardiac illnesses
      • 4.2.1.2. Growing availability of diagnostic services
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. High cost associated with the treatment of brugada syndrome
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Brugada Syndrome Industry Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Brugada Syndrome Market, by Diagnosis

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Brugada Syndrome Market, by Diagnosis, 2019-2032 (USD Billion)
  • 5.3. Electrocardiogram
    • 5.3.1. Global Brugada Syndrome Market, by Electrocardiogram, by Region, 2019-2032 (USD Billion)
  • 5.4. Electrophysiology test
    • 5.4.1. Global Brugada Syndrome Market, Electrophysiology test, by Region, 2019-2032 (USD Billion)
  • 5.5. Genetic testing
    • 5.5.1. Global Brugada Syndrome Market, Genetic testing, by Region, 2019-2032 (USD Billion)
  • 5.6. Others
    • 5.6.1. Global Brugada Syndrome Market, Others, by Region, 2019-2032 (USD Billion)

6. Global Brugada Syndrome Market, by Treatment

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Brugada Syndrome Market, by Treatment, 2019-2032 (USD Billion)
  • 6.3. Implantable cardioverter defibrillator
    • 6.3.1. Global Brugada Syndrome Market, by Implantable cardioverter defibrillator, by Region, 2019-2032 (USD Billion)
  • 6.4. Drug Therapy
    • 6.4.1. Global Brugada Syndrome Market, by Drug Therapy, by Region, 2019-2032 (USD Billion)
    • 6.4.2. Antiarrhythmic Drugs
      • 6.4.2.1. Global Brugada Syndrome Market, by Antiarrhythmic Drugs, by Region, 2019-2032 (USD Billion)
    • 6.4.3. Psychotropic Drugs
      • 6.4.3.1. Global Brugada Syndrome Market, by Psychotropic Drugs, by Region, 2019-2032 (USD Billion)
    • 6.4.4. Anaesthetics/Analgesics
      • 6.4.4.1. Global Brugada Syndrome Market, by Anaesthetics/Analgesics, by Region, 2019-2032 (USD Billion)
  • 6.5. Others
    • 6.5.1. Global Brugada Syndrome Market, by Others, by Region, 2019-2032 (USD Billion)

7. Global Brugada Syndrome Market, by End-Use

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Brugada Syndrome Market, by End-Use, 2019-2032 (USD Billion)
  • 7.3. Hospitals and clinics
    • 7.3.1. Global Brugada Syndrome Market, by Hospitals and clinics, By Region, 2019-2032 (USD Billion)
  • 7.4. Surgical centers
    • 7.4.1. Global Brugada Syndrome Market, by Surgical centers, By Region, 2019-2032 (USD Billion)
  • 7.5. Diagnostic centers
    • 7.5.1. Global Brugada Syndrome Market, by Diagnostic centers, By Region, 2019-2032 (USD Billion)
  • 7.6. Others
    • 7.6.1. Global Brugada Syndrome Market, by Others, By Region, 2019-2032 (USD Billion)

8. Global Brugada Syndrome Market, by Geography

  • 8.1. Key findings
  • 8.2. Introduction
    • 8.2.1. Brugada Syndrome Market Assessment, By Geography, 2019-2032 (USD Billion)
  • 8.3. Brugada Syndrome Market - North America
    • 8.3.1. North America: Brugada Syndrome Market, by Diagnosis, 2019-2032 (USD Billion)
    • 8.3.2. North America: Brugada Syndrome Market, by End-Use, 2019-2032 (USD Billion)
    • 8.3.3. North America: Brugada Syndrome Market, by Treatment, 2019-2032 (USD Billion)
    • 8.3.4. Brugada Syndrome Market - U.S.
      • 8.3.4.1. U.S.: Brugada Syndrome Market, by Diagnosis, 2019-2032 (USD Billion)
      • 8.3.4.2. U.S.: Brugada Syndrome Market, by End-Use, 2019-2032 (USD Billion)
      • 8.3.4.3. U.S.: Brugada Syndrome Market, by Treatment, 2019-2032 (USD Billion)
    • 8.3.5. Brugada Syndrome Market - Canada
      • 8.3.5.1. Canada: Brugada Syndrome Market, by Diagnosis, 2019-2032 (USD Billion)
      • 8.3.5.2. Canada.: Brugada Syndrome Market, by End-Use, 2019-2032 (USD Billion)
      • 8.3.5.3. Canada: Brugada Syndrome Market, by Treatment, 2019-2032 (USD Billion)
  • 8.4. Brugada Syndrome Market - Europe
    • 8.4.1. Europe: Brugada Syndrome Market, by Diagnosis, 2019-2032 (USD Billion)
    • 8.4.2. Europe.: Brugada Syndrome Market, by End-Use, 2019-2032 (USD Billion)
    • 8.4.3. Europe: Brugada Syndrome Market, by Treatment, 2019-2032 (USD Billion)
    • 8.4.4. Brugada Syndrome Market - UK
      • 8.4.4.1. UK: Brugada Syndrome Market, by Diagnosis, 2019-2032 (USD Billion)
      • 8.4.4.2. UK.: Brugada Syndrome Market, by End-Use, 2019-2032 (USD Billion)
      • 8.4.4.3. UK: Brugada Syndrome Market, by Treatment, 2019-2032 (USD Billion)
    • 8.4.5. Brugada Syndrome Market - France
      • 8.4.5.1. France: Brugada Syndrome Market, by Diagnosis, 2019-2032 (USD Billion)
      • 8.4.5.2. France.: Brugada Syndrome Market, by End-Use, 2019-2032 (USD Billion)
      • 8.4.5.3. France: Brugada Syndrome Market, by Treatment, 2019-2032 (USD Billion)
    • 8.4.6. Brugada Syndrome Market - Germany
      • 8.4.6.1. Germany: Brugada Syndrome Market, by Diagnosis, 2019-2032 (USD Billion)
      • 8.4.6.2. Germany.: Brugada Syndrome Market, by End-Use, 2019-2032 (USD Billion)
      • 8.4.6.3. Germany: Brugada Syndrome Market, by Treatment, 2019-2032 (USD Billion)
    • 8.4.7. Brugada Syndrome Market - Italy
      • 8.4.7.1. Italy: Brugada Syndrome Market, by Diagnosis, 2019-2032 (USD Billion)
      • 8.4.7.2. Italy.: Brugada Syndrome Market, by End-Use, 2019-2032 (USD Billion)
      • 8.4.7.3. Italy: Brugada Syndrome Market, by Treatment, 2019-2032 (USD Billion)
    • 8.4.8. Brugada Syndrome Market - Spain
      • 8.4.8.1. Spain: Brugada Syndrome Market, by Diagnosis, 2019-2032 (USD Billion)
      • 8.4.8.2. Spain.: Brugada Syndrome Market, by End-Use, 2019-2032 (USD Billion)
      • 8.4.8.3. Spain: Brugada Syndrome Market, by Treatment, 2019-2032 (USD Billion)
    • 8.4.9. Brugada Syndrome Market - Netherlands
      • 8.4.9.1. Netherlands: Brugada Syndrome Market, by Diagnosis, 2019-2032 (USD Billion)
      • 8.4.9.2. Netherlands.: Brugada Syndrome Market, by End-Use, 2019-2032 (USD Billion)
      • 8.4.9.3. Netherlands: Brugada Syndrome Market, by Treatment, 2019-2032 (USD Billion)
    • 8.4.10. Brugada Syndrome Market - Russia
      • 8.4.10.1. Russia: Brugada Syndrome Market, by Diagnosis, 2019-2032 (USD Billion)
      • 8.4.10.2. Russia.: Brugada Syndrome Market, by End-Use, 2019-2032 (USD Billion)
      • 8.4.10.3. Russia: Brugada Syndrome Market, by Treatment, 2019-2032 (USD Billion)
  • 8.5. Brugada Syndrome Market - Asia Pacific
    • 8.5.1. Asia Pacific: Brugada Syndrome Market, by Diagnosis, 2019-2032 (USD Billion)
    • 8.5.2. Asia Pacific.: Brugada Syndrome Market, by End-Use, 2019-2032 (USD Billion)
    • 8.5.3. Asia Pacific: Brugada Syndrome Market, by Treatment, 2019-2032 (USD Billion)
    • 8.5.4. Brugada Syndrome Market - China
      • 8.5.4.1. China: Brugada Syndrome Market, by Diagnosis, 2019-2032 (USD Billion)
      • 8.5.4.2. China.: Brugada Syndrome Market, by End-Use, 2019-2032 (USD Billion)
      • 8.5.4.3. China: Brugada Syndrome Market, by Treatment, 2019-2032 (USD Billion)
    • 8.5.5. Brugada Syndrome Market - India
      • 8.5.5.1. India: Brugada Syndrome Market, by Diagnosis, 2019-2032 (USD Billion)
      • 8.5.5.2. India.: Brugada Syndrome Market, by End-Use, 2019-2032 (USD Billion)
      • 8.5.5.3. India: Brugada Syndrome Market, by Treatment, 2019-2032 (USD Billion)
    • 8.5.6. Brugada Syndrome Market - Malaysia
      • 8.5.6.1. Malaysia: Brugada Syndrome Market, by Diagnosis, 2019-2032 (USD Billion)
      • 8.5.6.2. Malaysia.: Brugada Syndrome Market, by End-Use, 2019-2032 (USD Billion)
      • 8.5.6.3. Malaysia: Brugada Syndrome Market, by Treatment, 2019-2032 (USD Billion)
    • 8.5.7. Brugada Syndrome Market - Japan
      • 8.5.7.1. Japan: Brugada Syndrome Market, by Diagnosis, 2019-2032 (USD Billion)
      • 8.5.7.2. Japan.: Brugada Syndrome Market, by End-Use, 2019-2032 (USD Billion)
      • 8.5.7.3. Japan: Brugada Syndrome Market, by Treatment, 2019-2032 (USD Billion)
    • 8.5.8. Brugada Syndrome Market - Indonesia
      • 8.5.8.1. Indonesia: Brugada Syndrome Market, by Diagnosis, 2019-2032 (USD Billion)
      • 8.5.8.2. Indonesia.: Brugada Syndrome Market, by End-Use, 2019-2032 (USD Billion)
      • 8.5.8.3. Indonesia: Brugada Syndrome Market, by Treatment, 2019-2032 (USD Billion)
    • 8.5.9. Brugada Syndrome Market - South Korea
      • 8.5.9.1. South Korea: Brugada Syndrome Market, by Diagnosis, 2019-2032 (USD Billion)
      • 8.5.9.2. South Korea.: Brugada Syndrome Market, by End-Use, 2019-2032 (USD Billion)
      • 8.5.9.3. South Korea: Brugada Syndrome Market, by Treatment, 2019-2032 (USD Billion)
  • 8.6. Brugada Syndrome Market - Middle East & Africa
    • 8.6.1. Middle East & Africa: Brugada Syndrome Market, by Diagnosis, 2019-2032 (USD Billion)
    • 8.6.2. Middle East & Africa.: Brugada Syndrome Market, by End-Use, 2019-2032 (USD Billion)
    • 8.6.3. Middle East & Africa: Brugada Syndrome Market, by Treatment, 2019-2032 (USD Billion)
    • 8.6.4. Brugada Syndrome Market - Saudi Arabia
      • 8.6.4.1. Saudi Arabia: Brugada Syndrome Market, by Diagnosis, 2019-2032 (USD Billion)
      • 8.6.4.2. Saudi Arabia.: Brugada Syndrome Market, by End-Use, 2019-2032 (USD Billion)
      • 8.6.4.3. Saudi Arabia: Brugada Syndrome Market, by Treatment, 2019-2032 (USD Billion)
    • 8.6.5. Brugada Syndrome Market - UAE
      • 8.6.5.1. UAE: Brugada Syndrome Market, by Diagnosis, 2019-2032 (USD Billion)
      • 8.6.5.2. UAE.: Brugada Syndrome Market, by End-Use, 2019-2032 (USD Billion)
      • 8.6.5.3. UAE: Brugada Syndrome Market, by Treatment, 2019-2032 (USD Billion)
    • 8.6.6. Brugada Syndrome Market - Israel
      • 8.6.6.1. Israel: Brugada Syndrome Market, by Diagnosis, 2019-2032 (USD Billion)
      • 8.6.6.2. Israel.: Brugada Syndrome Market, by End-Use, 2019-2032 (USD Billion)
      • 8.6.6.3. Israel: Brugada Syndrome Market, by Treatment, 2019-2032 (USD Billion)
    • 8.6.7. Brugada Syndrome Market - South Africa
      • 8.6.7.1. South Africa: Brugada Syndrome Market, by Diagnosis, 2019-2032 (USD Billion)
      • 8.6.7.2. South Africa.: Brugada Syndrome Market, by End-Use, 2019-2032 (USD Billion)
      • 8.6.7.3. South Africa: Brugada Syndrome Market, by Treatment, 2019-2032 (USD Billion)
  • 8.7. Brugada Syndrome Market - Latin America
    • 8.7.1. Latin America: Brugada Syndrome Market, by Diagnosis, 2019-2032 (USD Billion)
    • 8.7.2. Latin America.: Brugada Syndrome Market, by End-Use, 2019-2032 (USD Billion)
    • 8.7.3. Latin America: Brugada Syndrome Market, by Treatment, 2019-2032 (USD Billion)
    • 8.7.4. Brugada Syndrome Market - Mexico
      • 8.7.4.1. Mexico: Brugada Syndrome Market, by Diagnosis, 2019-2032 (USD Billion)
      • 8.7.4.2. Mexico.: Brugada Syndrome Market, by End-Use, 2019-2032 (USD Billion)
      • 8.7.4.3. Mexico: Brugada Syndrome Market, by Treatment, 2019-2032 (USD Billion)
    • 8.7.5. Brugada Syndrome Market - Brazil
      • 8.7.5.1. Brazil: Brugada Syndrome Market, by Diagnosis, 2019-2032 (USD Billion)
      • 8.7.5.2. Brazil.: Brugada Syndrome Market, by End-Use, 2019-2032 (USD Billion)
      • 8.7.5.3. Brazil: Brugada Syndrome Market, by Treatment, 2019-2032 (USD Billion)
    • 8.7.6. Brugada Syndrome Market - Argentina
      • 8.7.6.1. Argentina: Brugada Syndrome Market, by Diagnosis, 2019-2032 (USD Billion)
      • 8.7.6.2. Argentina.: Brugada Syndrome Market, by End-Use, 2019-2032 (USD Billion)
      • 8.7.6.3. Argentina: Brugada Syndrome Market, by Treatment, 2019-2032 (USD Billion)

9. Competitive Landscape

  • 9.1. Expansion and Acquisition Analysis
    • 9.1.1. Expansion
    • 9.1.2. Acquisitions
  • 9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

  • 10.1. Abbott
    • 10.1.1. Company Overview
    • 10.1.2. Financial PerTreatmentance
    • 10.1.3. Treatment Benchmarking
    • 10.1.4. Recent Development
  • 10.2. Boehringer Ingelheim International
    • 10.2.1. Company Overview
    • 10.2.2. Financial PerTreatmentance
    • 10.2.3. Treatment Benchmarking
    • 10.2.4. Recent Development
  • 10.3. Catalyst Pharmaceuticals Inc
    • 10.3.1. Company Overview
    • 10.3.2. Financial PerTreatmentance
    • 10.3.3. Treatment Benchmarking
    • 10.3.4. Recent Development
  • 10.4. Ionis Pharmaceuticals
    • 10.4.1. Company Overview
    • 10.4.2. Financial PerTreatmentance
    • 10.4.3. Treatment Benchmarking
    • 10.4.4. Recent Development
  • 10.5. Leadiant Biosciences Inc
    • 10.5.1. Company Overview
    • 10.5.2. Financial PerTreatmentance
    • 10.5.3. Treatment Benchmarking
    • 10.5.4. Recent Development
  • 10.6. Natera Inc
    • 10.6.1. Company Overview
    • 10.6.2. Financial PerTreatmentance
    • 10.6.3. Treatment Benchmarking
    • 10.6.4. Recent Development
  • 10.7. Novo Nordisk A/S
    • 10.7.1. Company Overview
    • 10.7.2. Financial PerTreatmentance
    • 10.7.3. Treatment Benchmarking
    • 10.7.4. Recent Development
  • 10.8. Pfizer Inc
    • 10.8.1. Company Overview
    • 10.8.2. Financial PerTreatmentance
    • 10.8.3. Treatment Benchmarking
    • 10.8.4. Recent Development
  • 10.9. PTC Therapeutics
    • 10.9.1. Company Overview
    • 10.9.2. Financial PerTreatmentance
    • 10.9.3. Treatment Benchmarking
    • 10.9.4. Recent Development
  • 10.10. Roche
    • 10.10.1. Company Overview
    • 10.10.2. Financial PerTreatmentance
    • 10.10.3. Treatment Benchmarking
    • 10.10.4. Recent Development
  • 10.11. Salarius Pharmaceuticals Inc
    • 10.11.1. Company Overview
    • 10.11.2. Financial PerTreatmentance
    • 10.11.3. Treatment Benchmarking
    • 10.11.4. Recent Development
  • 10.12. Takeda Pharmaceuticals
    • 10.12.1. Company Overview
    • 10.12.2. Financial PerTreatmentance
    • 10.12.3. Treatment Benchmarking
    • 10.12.4. Recent Development
  • 10.13. Novartis AG
    • 10.13.1. Company Overview
    • 10.13.2. Financial PerTreatmentance
    • 10.13.3. Treatment Benchmarking
    • 10.13.4. Recent Development

List of Tables

  • Table 1 Global Brugada Syndrome Market, by Diagnosis, 2019-2032 (USD Billion)
  • Table 2 Global Brugada Syndrome Market, by Treatment, 2019-2032 (USD Billion)
  • Table 3 Global Brugada Syndrome Market, by End-Use, 2019-2032 (USD Billion)
  • Table 4 Brugada Syndrome Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Table 5 North America: Brugada Syndrome Market, by Diagnosis, 2019-2032 (USD Billion)
  • Table 6 North America: Brugada Syndrome Market, by Treatment, 2019-2032 (USD Billion)
  • Table 7 North America: Brugada Syndrome Market, by End-Use, 2019-2032 (USD Billion)
  • Table 8 U.S.: Brugada Syndrome Market, by Diagnosis, 2019-2032 (USD Billion)
  • Table 9 U.S.: Brugada Syndrome Market, by Treatment, 2019-2032 (USD Billion)
  • Table 10 U.S.: Brugada Syndrome Market, by End-Use, 2019-2032 (USD Billion)
  • Table 11 Canada: Brugada Syndrome Market, by Diagnosis, 2019-2032 (USD Billion)
  • Table 12 Canada: Brugada Syndrome Market, by Treatment, 2019-2032 (USD Billion)
  • Table 13 Canada: Brugada Syndrome Market, by End-Use, 2019-2032 (USD Billion)
  • Table 14 Europe: Brugada Syndrome Market, by Diagnosis, 2019-2032 (USD Billion)
  • Table 15 Europe: Brugada Syndrome Market, by Treatment, 2019-2032 (USD Billion)
  • Table 16 Europe: Brugada Syndrome Market, by End-Use, 2019-2032 (USD Billion)
  • Table 17 UK: Brugada Syndrome Market, by Diagnosis, 2019-2032 (USD Billion)
  • Table 18 UK: Brugada Syndrome Market, by Treatment, 2019-2032 (USD Billion)
  • Table 19 UK: Brugada Syndrome Market, by End-Use, 2019-2032 (USD Billion)
  • Table 20 France: Brugada Syndrome Market, by Diagnosis, 2019-2032 (USD Billion)
  • Table 21 France: Brugada Syndrome Market, by Treatment, 2019-2032 (USD Billion)
  • Table 22 France: Brugada Syndrome Market, by End-Use, 2019-2032 (USD Billion)
  • Table 23 Germany: Brugada Syndrome Market, by Diagnosis, 2019-2032 (USD Billion)
  • Table 24 Germany: Brugada Syndrome Market, by Treatment, 2019-2032 (USD Billion)
  • Table 25 Germany: Brugada Syndrome Market, by End-Use, 2019-2032 (USD Billion)
  • Table 26 Italy: Brugada Syndrome Market, by Diagnosis, 2019-2032 (USD Billion)
  • Table 27 Italy: Brugada Syndrome Market, by Treatment, 2019-2032 (USD Billion)
  • Table 28 Italy: Brugada Syndrome Market, by End-Use, 2019-2032 (USD Billion)
  • Table 29 Spain: Brugada Syndrome Market, by Diagnosis, 2019-2032 (USD Billion)
  • Table 30 Spain: Brugada Syndrome Market, by Treatment, 2019-2032 (USD Billion)
  • Table 31 Spain: Brugada Syndrome Market, by End-Use, 2019-2032 (USD Billion)
  • Table 32 Netherlands: Brugada Syndrome Market, by Diagnosis, 2019-2032 (USD Billion)
  • Table 33 Netherlands: Brugada Syndrome Market, by Treatment, 2019-2032 (USD Billion)
  • Table 34 Netherlands: Brugada Syndrome Market, by End-Use, 2019-2032 (USD Billion)
  • Table 35 Russia: Brugada Syndrome Market, by Diagnosis, 2019-2032 (USD Billion)
  • Table 36 Russia: Brugada Syndrome Market, by Treatment, 2019-2032 (USD Billion)
  • Table 37 Russia: Brugada Syndrome Market, by End-Use, 2019-2032 (USD Billion)
  • Table 38 Asia Pacific: Brugada Syndrome Market, by Diagnosis, 2019-2032 (USD Billion)
  • Table 39 Asia Pacific: Brugada Syndrome Market, by Treatment, 2019-2032 (USD Billion)
  • Table 40 Asia Pacific: Brugada Syndrome Market, by End-Use, 2019-2032 (USD Billion)
  • Table 41 China: Brugada Syndrome Market, by Diagnosis, 2019-2032 (USD Billion)
  • Table 42 China: Brugada Syndrome Market, by Treatment, 2019-2032 (USD Billion)
  • Table 43 China: Brugada Syndrome Market, by End-Use, 2019-2032 (USD Billion)
  • Table 44 India: Brugada Syndrome Market, by Diagnosis, 2019-2032 (USD Billion)
  • Table 45 India: Brugada Syndrome Market, by Treatment, 2019-2032 (USD Billion)
  • Table 46 India: Brugada Syndrome Market, by End-Use, 2019-2032 (USD Billion)
  • Table 47 Malaysia: Brugada Syndrome Market, by Diagnosis, 2019-2032 (USD Billion)
  • Table 48 Malaysia: Brugada Syndrome Market, by Treatment, 2019-2032 (USD Billion)
  • Table 49 Malaysia: Brugada Syndrome Market, by End-Use, 2019-2032 (USD Billion)
  • Table 50 Japan: Brugada Syndrome Market, by Diagnosis, 2019-2032 (USD Billion)
  • Table 51 Japan: Brugada Syndrome Market, by Treatment, 2019-2032 (USD Billion)
  • Table 52 Japan: Brugada Syndrome Market, by End-Use, 2019-2032 (USD Billion)
  • Table 53 Indonesia: Brugada Syndrome Market, by Diagnosis, 2019-2032 (USD Billion)
  • Table 54 Indonesia: Brugada Syndrome Market, by Treatment, 2019-2032 (USD Billion)
  • Table 55 Indonesia: Brugada Syndrome Market, by End-Use, 2019-2032 (USD Billion)
  • Table 56 South Korea: Brugada Syndrome Market, by Diagnosis, 2019-2032 (USD Billion)
  • Table 57 South Korea: Brugada Syndrome Market, by Treatment, 2019-2032 (USD Billion)
  • Table 58 South Korea: Brugada Syndrome Market, by End-Use, 2019-2032 (USD Billion)
  • Table 59 Middle East & Africa: Brugada Syndrome Market, by Diagnosis, 2019-2032 (USD Billion)
  • Table 60 Middle East & Africa: Brugada Syndrome Market, by Treatment, 2019-2032 (USD Billion)
  • Table 61 Middle East & Africa: Brugada Syndrome Market, by End-Use, 2019-2032 (USD Billion)
  • Table 62 Saudi Arabia: Brugada Syndrome Market, by Diagnosis, 2019-2032 (USD Billion)
  • Table 63 Saudi Arabia: Brugada Syndrome Market, by Treatment, 2019-2032 (USD Billion)
  • Table 64 Saudi Arabia: Brugada Syndrome Market, by End-Use, 2019-2032 (USD Billion)
  • Table 65 UAE: Brugada Syndrome Market, by Diagnosis, 2019-2032 (USD Billion)
  • Table 66 UAE: Brugada Syndrome Market, by Treatment, 2019-2032 (USD Billion)
  • Table 67 UAE: Brugada Syndrome Market, by End-Use, 2019-2032 (USD Billion)
  • Table 68 Israel: Brugada Syndrome Market, by Diagnosis, 2019-2032 (USD Billion)
  • Table 69 Israel: Brugada Syndrome Market, by Treatment, 2019-2032 (USD Billion)
  • Table 70 Israel: Brugada Syndrome Market, by End-Use, 2019-2032 (USD Billion)
  • Table 71 South Africa: Brugada Syndrome Market, by Diagnosis, 2019-2032 (USD Billion)
  • Table 72 South Africa: Brugada Syndrome Market, by Treatment, 2019-2032 (USD Billion)
  • Table 73 South Africa: Brugada Syndrome Market, by End-Use, 2019-2032 (USD Billion)
  • Table 74 Latin America: Brugada Syndrome Market, by Diagnosis, 2019-2032 (USD Billion)
  • Table 75 Latin America: Brugada Syndrome Market, by Treatment, 2019-2032 (USD Billion)
  • Table 76 Latin America: Brugada Syndrome Market, by End-Use, 2019-2032 (USD Billion)
  • Table 77 Mexico: Brugada Syndrome Market, by Diagnosis, 2019-2032 (USD Billion)
  • Table 78 Mexico: Brugada Syndrome Market, by Treatment, 2019-2032 (USD Billion)
  • Table 79 Mexico: Brugada Syndrome Market, by End-Use, 2019-2032 (USD Billion)
  • Table 80 Brazil: Brugada Syndrome Market, by Diagnosis, 2019-2032 (USD Billion)
  • Table 81 Brazil: Brugada Syndrome Market, by Treatment, 2019-2032 (USD Billion)
  • Table 82 Brazil: Brugada Syndrome Market, by End-Use, 2019-2032 (USD Billion)
  • Table 83 Argentina: Brugada Syndrome Market, by Diagnosis, 2019-2032 (USD Billion)
  • Table 84 Argentina: Brugada Syndrome Market, by Treatment, 2019-2032 (USD Billion)
  • Table 85 Argentina: Brugada Syndrome Market, by End-Use, 2019-2032 (USD Billion)

List of Figures

  • Figure 1. Global Brugada Syndrome Market, 2019-2032 (USD Billion)
  • Figure 2. Integrated Ecosystem
  • Figure 3. Research Methodology: Top-Down & Bottom-Up Approach
  • Figure 4. Market by Geography
  • Figure 5. Porter's Five Forces
  • Figure 6. Market by Treatment
  • Figure 7. Global Brugada Syndrome Market, by Treatment, 2021 & 2030 (USD Billion)
  • Figure 8. Market by Diagnosis
  • Figure 9. Global Brugada Syndrome Market, by Diagnosis, 2021 & 2030 (USD Billion)
  • Figure 10. Market by End-Use
  • Figure 11. Global Brugada Syndrome Market, by End-Use, 2021 & 2030 (USD Billion)
  • Figure 12. Brugada Syndrome Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Figure 13. Strategic Analysis - Brugada Syndrome Market